Skin and soft tissue infections: Current therapeutic options;Infezioni della cute e dei tessuti molli: Opzioni terapeutiche

Infezioni in Medicina

Volumn 16, Issue 2, 2008, Pages 65-73

  Esposito, Silvano ^a   Noviello, Silvana ^a   Leone, Sebastiano ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Daptomycin; Guidelines; Linezolid; Skin and soft tissue infections; Tigecycline

Indexed keywords

AZTREONAM; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ICLAPRIM; LINEZOLID; MACROLIDE; MINOCYCLINE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ABSCESS; ANTIBIOTIC RESISTANCE; BACTEROIDES; CELLULITIS; CLOSTRIDIUM; DECUBITUS; DISEASE SEVERITY; DRUG COST; ERYSIPELAS; FOLLICULITIS; FOURNIER GANGRENE; FURUNCULOSIS; GAS GANGRENE; HUMAN; IMMUNE DEFICIENCY; IMPETIGO; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYOSITIS; NECROTIZING FASCIITIS; POLYMYOSITIS; PRACTICE GUIDELINE; PSEUDOMONAS; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; SURGICAL INFECTION; VENOUS STASIS;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DAPTOMYCIN; HUMANS; METHICILLIN RESISTANCE; MIDDLE AGED; MINOCYCLINE; OXAZOLIDINONES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 47149113644     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Eron L.J., Lipsky B.A., Low D.E., et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J. Antimicrob. Chemother. 52 (Suppl. S1), i3-i17, 2003.
2. Di Nubile M.J., Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother. 53 Suppl 2, ii 37-50, 2004.
3. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41, 1373-1406, 2005.
4. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63(14), 1459-1480, 2003.
5. Rennie RP, Jones RN, Mutnick AH; SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45(4), 287-293, 2003.
6. Jones M.E., Schmitz F.J., Fluit A.C., et al. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group. Eur. J. Clin. Microbiol. Infect. Dis. 18(6), 403-408, 1999.
7. Hunt C, Dionne M., Delorme M., et al. Four Pediatric Deaths From Community-Acquired Methicillin-Resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. JAMA 282 (12), 1123-1125, 1999.
8. Culepper R., Nolan R., Chapman S., et al. Methicillin-Resistant Staphylococcus aureus Skin or Soft Tissue Infections in a State Prison - Mississippi, 2000. JAMA 287 (2), 181-182, 2002.
9. Centers for Disease Control and Prevention (CDC). Methicillin-Resistant Staphylococcus aureus Infections in Correctional Facilities - Georgia, California, and Texas, 2001-2003. Morb. Mortal. Wkly Rep. 52 (41), 992-996, 2003.
10. Centers for Disease Control and Prevention. Public health dispatch: outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections - Los Angeles County, California, 2002-2003. JAMA 289(11), 1377, 2003.
11. Centers for Disease Control and Prevention (CDC). Methicillin-Resistant Staphylococcus aureus Infections Among Competitive Sports participants - Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. Morb. Mortal. Wkly Rep. 52(33), 793-795, 2003.
12. Naimi T.S., Ledell k.H., Como-Sabetti K., et al. Comparison of community- and health care-associated methicillin resistano Staphylococcus aureus infection. JAMA 290, 2976-2984, 2003.
13. Voyich J.M., Otto M., Mathema B., et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis. 194, 1761-1770, 2006.
14. Moran G.J., Amii R.N., Abrahamian F.M., et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis. 11 (6), 928-930, 2005.
15. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36(1), 53-59, 2003.
16. Whitby M., McLaws M.L., Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med. J. Aust. 175 (5), 264-267, 2001.
17. Daum R.S. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. New Engl. J. Med. 357 (4), 380-390, 2007.
18. Weigelt J., Kaafarani H.M., Itani K.M., et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188 (6), 760-766, 2005.
19. Weigelt J., Itani K.M., Stevens D. et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49 (6), 2260-2266, 2005.
20. Itani K.M., Weigelt J., Li J.Z., et al. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MR-SA). Int. J. Antimicrob. Agents 26 (6), 442-448, 2005.
21. Ellis-Grosse E.J., Babinchak T., Dartois N., et al. The efficacy and safety of Tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with Vancomycin-Aztreonam. Clin. Infect. Dis. 41 (suppl. 5), S341-S353, 2005.
22. Arbeit R.D., Maki D., Tally F.P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38, 1673-1681, 2004.
23. Krige J.E., Lindfield K., Friedrich L., et al. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Cwrr. Med. Res. Opin. 23 (9), 2147-2156, 2007.
24. Davis S.L., McKinnon P.S., Hall L.M., et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 27(12), 1611-1618, 2007.
25. Lipsky B.A., Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. 55, 240-245, 2005.
26. Owens R.C., Lamp K.C., Friedrich L.V. et al. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am. J. Med. 120 (10A), S6-S12, 2007.